Hookipa Biotech has appointed Dr Igor Matushansky as its global head, research and development in a role that focuses on strategic priorities.
Previously global head of translational development for oncology at Daiichi Sankyo, Matushansky has experience in early oncology therapeutic programmes, strategy and development.
He said: “It’s an exciting time to join the Hookipa team and I am very eager to share my experience in drug development to further its mission to help patients.”
Matushansky has also previously worked for Novartis’ oncology translational medicine unit as clinical programme lead.
Joern Aldag, CEO at Hookipa Biotech, said: “Dr Matushansky’s valuable experience heading up R&D units at big pharma companies coupled with his significant immuno-oncology expertise will be transformative to Hookipa as we expand our company from prophylactic to therapeutic immuno-oncology focused therapies.
“I look forward to working together to achieve our goals and strategic priorities for 2017 and beyond.”